Disclaimer: This information is intended for educational purposes and as a clinical reference for healthcare professionals. It is based on current medical knowledge and guidelines. However, clinical situations are complex and dynamic. This content should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always exercise independent clinical judgment and consult with appropriate specialists. Drug dosages and indications may change, and clinicians must refer to the latest prescribing information and local guidelines.

---

RSV Recent Advances

Overview

• Definition: Respiratory Syncytial Virus (RSV) is a common, highly contagious RNA virus of the Pneumoviridae family, a leading cause of acute lower respiratory tract infection (LRTI) in infants and young children, and a significant cause of respiratory illness in older adults and immunocompromised individuals. It typically causes mild, cold-like symptoms but can lead to severe bronchiolitis and pneumonia.
• Epidemiology: RSV is seasonal, typically peaking in fall and winter in temperate climates. It causes millions of infections globally each year, leading to substantial hospitalizations and deaths, particularly in infants and older adults. Recent data highlight:
  • Infants: Nearly all children are infected by age 2. RSV is the most common cause of bronchiolitis and pneumonia in infants <1 year, accounting for 50,000-80,000 hospitalizations annually in the U.S.
  • Older Adults: RSV is increasingly recognized as a major cause of respiratory illness in adults ≥65 years, with an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually in the U.S., comparable to influenza burden in some seasons.
  • Global Burden: Approximately 3.6 million hospitalizations and 100,000 deaths annually in children globally, with high burden in low- and middle-income countries.
• Classification: RSV is classified into two major antigenic subgroups, A and B, which co-circulate and contribute to outbreaks. Infection with one subgroup does not confer complete immunity to the other.

Pathophysiology

• Mechanism: RSV is a non-segmented, negative-sense RNA virus. It replicates in the respiratory epithelial cells, causing inflammation, necrosis, and sloughing of cells. This leads to edema, mucus plugging, and sloughing of cellular debris, particularly in small airways (bronchioles), resulting in airway obstruction, atelectasis, and hyperinflation. Recent advances in understanding the F (fusion) protein have been critical for vaccine and monoclonal antibody development, as this protein is highly conserved and essential for viral entry into host cells and cell-to-cell spread.
• Risk Factors:
  • For Severe Disease in Infants: Prematurity (<37 weeks gestation), congenital heart disease (especially hemodynamically significant), chronic lung disease of prematurity (bronchopulmonary dysplasia), neuromuscular disorders, immunodeficiency, certain genetic disorders (e.g., Down syndrome), young age (<6 months), male sex, lack of breastfeeding, exposure to tobacco smoke, crowded living conditions.
  • For Severe Disease in Older Adults: Age ≥65 years, chronic underlying medical conditions (e.g., chronic obstructive pulmonary disease, asthma, congestive heart failure, diabetes, chronic kidney disease, neurological disorders), immunocompromised states (e.g., cancer, organ transplant recipients, HIV/AIDS).
• Protective Factors:
  • Breastfeeding (provides some passive immunity and anti-inflammatory effects).
  • Improved hygiene and reduced crowded living conditions.
  • Recent Advance: Passive immunoprophylaxis (monoclonal antibodies) and active immunization (vaccines) are now primary protective factors.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Rhinorrhea, congestion, cough, fever, decreased appetite, wheezing, tachypnea, retractions.
• Early Signs: Typically resembles a common cold: rhinorrhea, mild cough, low-grade fever.
• Advanced Signs: As the infection progresses to the lower respiratory tract, signs of respiratory distress develop: increased work of breathing (tachypnea, nasal flaring, retractions – subcostal, intercostal, supraclavicular), wheezing, crackles, grunting, cyanosis (late sign). Apnea can be an initial or prominent symptom in very young infants.
• Atypical Presentations:
  • Young Infants: May present with irritability, lethargy, poor feeding, and recurrent apnea without significant respiratory signs.
  • Older Adults: May present with exacerbation of underlying chronic lung or heart disease, generalized weakness, fatigue, or confusion, in addition to or instead of classic respiratory symptoms. Fever may be absent.

Physical Examination

• Inspection: Tachypnea, nasal flaring, retractions, accessory muscle use, cyanosis. May observe increased anteroposterior chest diameter (hyperinflation).
• Palpation: Normal.
• Auscultation: Wheezing (often expiratory, but can be inspiratory), crackles (rales), rhonchi. Breath sounds may be diminished in severe disease. Prolonged expiration.

Diagnostic Approach

History Taking

• Key Questions: Onset and progression of symptoms, fever, feeding/hydration status, urine output, past medical history (prematurity, chronic lung/heart disease, immunodeficiency), vaccination status (especially influenza and COVID-19 to rule out), potential exposures (sick contacts). For older adults, history of chronic conditions and functional status.
• Red Flags: Severe respiratory distress (marked retractions, grunting, central cyanosis), decreased level of consciousness, poor feeding/dehydration, apnea episodes (especially in infants), signs of secondary bacterial infection (e.g., persistent high fever, new crackles in a specific lobe).

Laboratory Tests

• First-Line: Rapid antigen detection tests (RADTs) or molecular assays (PCR) from nasopharyngeal swab/aspirate. PCR is highly sensitive and specific and is preferred for definitive diagnosis. Often included in multiplex respiratory virus panels.
• Confirmatory: Reverse transcription polymerase chain reaction (RT-PCR) is the gold standard for sensitivity and specificity, allowing for differentiation from other respiratory viruses.
• Monitoring: Not routinely indicated unless complications are suspected. Blood tests (CBC, inflammatory markers) are non-specific and usually not helpful for routine diagnosis but may be considered for severe illness or suspected bacterial superinfection.

Imaging

• Recommended: Chest X-ray (CXR) is not routinely recommended for uncomplicated bronchiolitis but may be considered in severe cases, atypical presentations, or to rule out complications (e.g., bacterial pneumonia, pneumothorax). Findings may include hyperinflation, peribronchial cuffing, atelectasis, and patchy infiltrates.
• Advanced: CT scan or other advanced imaging is generally not indicated for RSV and should be reserved for specific clinical questions (e.g., persistent collapse, suspected foreign body aspiration, or other lung pathologies).

Management

Acute Management

• Immediate: Focus on supportive care. Maintain adequate oxygenation and hydration. Assess severity using clinical scoring systems (e.g., Respiratory Distress Assessment Instrument for infants).
• Stabilization:
  • Oxygen Therapy: Administer supplemental oxygen to maintain SpO2 ≥90% (or ≥92% for infants with cardiac/pulmonary comorbidities). Can be delivered via nasal cannula, high-flow nasal cannula (HFNC), or non-rebreather mask. HFNC has shown benefit in reducing need for invasive ventilation in some cases.
  • Fluid Management: Oral or intravenous fluids to prevent dehydration, especially in infants with tachypnea affecting feeding.
  • Airway Clearance: Nasal suctioning, especially before feeds.
  • Medications (Limited Role): Bronchodilators (e.g., albuterol) are generally NOT recommended for routine use in bronchiolitis due to lack of consistent benefit, but a trial may be considered in infants with a strong history of asthma/atopy or those who respond clinically. Corticosteroids are NOT recommended. Antivirals (e.g., ribavirin) are rarely used, primarily in severely immunocompromised patients, due to toxicity and limited efficacy.
• Emergency: For severe respiratory failure, prepare for advanced airway management (intubation and mechanical ventilation). Consider CPAP or BiPAP as a bridge or alternative to intubation in select patients.

Chronic Management

• Pharmacological:
  • No specific chronic pharmacological treatment for RSV infection.
  • Prophylaxis is key for prevention (see "Prevention" section below).
• Non-pharmacological: Long-term follow-up for infants with severe RSV may involve monitoring for recurrent wheezing episodes, which are more common in this group. Family education on early recognition of respiratory distress and smoke avoidance.
• Monitoring: For infants hospitalized with RSV, monitor respiratory rate, heart rate, oxygen saturation, work of breathing, and feeding tolerance until stable for discharge. Long-term, monitor for recurrent respiratory symptoms.

Treatment Algorithms

• First-Line: Supportive care (oxygen, hydration, airway management).
• Second-Line: High-flow nasal cannula for moderate to severe respiratory distress.
• Refractory Cases: Consider non-invasive positive pressure ventilation (CPAP/BiPAP) or intubation and mechanical ventilation for impending or established respiratory failure. Limited evidence for specific rescue therapies for persistent severe disease.

Complications

• Common: Dehydration, otitis media, secondary bacterial pneumonia, apnea (especially in young infants), exacerbation of underlying chronic lung or heart conditions.
• Serious: Respiratory failure requiring mechanical ventilation, acute respiratory distress syndrome (ARDS), myocarditis, encephalopathy.
• Long-term: Increased risk of recurrent wheezing and asthma in childhood after severe RSV bronchiolitis. This association is well-established, though the causal link and mechanisms are still under investigation.

Prognosis

• Factors: Age (younger infants at higher risk), prematurity, presence of underlying cardiopulmonary disease or immunodeficiency, severity of acute illness.
• Survival: Most infants and children recover completely. Mortality rates are low in healthy children (<0.1%) but higher in high-risk groups (up to 2-4% in infants with congenital heart disease or chronic lung disease) and older adults (3-10% of hospitalized cases).
• Quality of Life: While most recover without long-term issues, a significant proportion of infants hospitalized with RSV develop recurrent wheezing and reduced exercise tolerance in the years following infection, impacting quality of life. Older adults may experience prolonged fatigue and functional decline.

Prevention

This is where significant recent advances have occurred.

• Primary (Preventing Initial Occurrence):

  • Hand Hygiene & Infection Control: Frequent hand washing, avoiding close contact with sick individuals, and cleaning contaminated surfaces.
  • Smoking Cessation: Avoidance of exposure to tobacco smoke.
  • Immunoprophylaxis (Monoclonal Antibodies):
    • Palivizumab (Synagis): A monoclonal antibody (mAb) administered monthly (15 mg/kg IM) during RSV season to very high-risk infants. Historically used, but nirsevimab is largely replacing it for broader infant protection.
    • Nirsevimab (Beyfortus): (Major Advance - FDA approved 2023, ACIP recommended 2023) A single-dose, long-acting monoclonal antibody targeting the F protein, providing protection for an entire RSV season.
      • Dosage:
        • Infants weighing <5 kg: 50 mg IM single dose.
        • Infants weighing ≥5 kg: 100 mg IM single dose.
      • Indications (ACIP Recommendations):
        1. All infants younger than 8 months born during or entering their first RSV season.
        2. Infants and children aged 8–19 months who are at increased risk for severe RSV disease (e.g., chronic lung disease, severe immunocompromise) entering their second RSV season.
      • Efficacy: Demonstrated 70-80% reduction in RSV-associated LRTI hospitalizations and severe LRTI.
  • Active Immunization (Vaccines):
    • Maternal RSV Vaccine (Abrysvo - Pfizer): (Major Advance - FDA approved 2023, ACIP recommended 2023) A bivalent vaccine targeting RSV A and B F proteins.
      • Dosage: 120 mcg IM single dose.
      • Indications (ACIP Recommendations): Pregnant individuals 32 through 36 weeks gestation (optimally September-January in most of the continental US) to protect their infants from RSV LRTI.
      • Efficacy: Demonstrated ~82% efficacy in preventing severe RSV LRTI in infants within 90 days of birth and ~69% within 180 days.
    • RSV Vaccines for Older Adults (≥60 years): (Major Advance - FDA approved 2023, ACIP recommended 2023) Both target the F protein.
      • Arexvy (GSK): Adjuvanted vaccine.
        • Dosage: 120 mcg IM single dose.
        • Indications (ACIP Recommendations): Adults aged ≥60 years, using shared clinical decision-making.
        • Efficacy: Demonstrated ~83% efficacy against RSV-associated LRTI and ~94% against severe LRTI in individuals ≥60 years.
      • Abrysvo (Pfizer): Non-adjuvanted vaccine.
        • Dosage: 120 mcg IM single dose.
        • Indications (ACIP Recommendations): Adults aged ≥60 years, using shared clinical decision-making.
        • Efficacy: Demonstrated ~67% efficacy against RSV-associated LRTI and ~85% against severe LRTI in individuals ≥60 years.

• Secondary (Early Detection and Intervention): No specific secondary prevention beyond early diagnosis and supportive care for symptoms.

• Tertiary (Preventing Complications): Close monitoring of at-risk patients, timely intervention with oxygen/hydration, and prompt management of complications like bacterial superinfection.

Special Populations

• Pediatric:
  • Infants <8 months: Primary target for universal nirsevimab administration during their first RSV season.
  • Infants/Children 8-19 months: Nirsevimab for those with increased risk for severe RSV in their second RSV season.
  • Premature Infants: Historically a key target for palivizumab; now largely covered by nirsevimab or maternal vaccination.
• Geriatric: Adults ≥60 years are a primary target for newly available RSV vaccines (Arexvy, Abrysvo) using shared clinical decision-making.
• Pregnancy: Pregnant individuals 32-36 weeks gestation are recommended to receive the maternal RSV vaccine (Abrysvo) to provide passive immunity to their newborns.
• Comorbidities:
  • Immunocompromised: Higher risk of severe and prolonged RSV disease. May require consideration for specific prophylaxis (nirsevimab for infants/children) or specialized management in adults (e.g., antivirals, though limited efficacy). Older adults with comorbidities are priority for RSV vaccination.
  • Chronic Cardiopulmonary Conditions: Infants with hemodynamically significant congenital heart disease or chronic lung disease, and adults with COPD/CHF, are at higher risk for severe RSV and are key target groups for prevention.

Clinical Pearls

• Diagnostic: In young infants presenting with apnea without clear respiratory signs, consider RSV. For older adults, RSV symptoms can be subtle and mimic other respiratory illnesses; maintain a high index of suspicion, especially during RSV season.
• Treatment: Remember that supportive care remains the cornerstone of RSV management for acute illness. Avoid routine use of bronchodilators or corticosteroids for bronchiolitis. Focus resources on oxygen, hydration, and airway clearance.
• Pitfalls:
  • Over-prescribing unnecessary medications (e.g., antibiotics for viral bronchiolitis).
  • Delaying critical supportive interventions, especially oxygen therapy.
  • Underestimating the burden of RSV in older adults, who may present with atypical symptoms.
  • Missing opportunities for prevention: Ensure eligible infants receive nirsevimab and eligible pregnant individuals/older adults receive RSV vaccines as per current guidelines. Understand the nuances of each prophylactic agent's indications and optimal timing.

Recent Updates

• Guidelines:
  • ACIP Recommendations (Advisory Committee on Immunization Practices, CDC, 2023):
    • Universal recommendation for nirsevimab for all infants <8 months.
    • Recommendation for nirsevimab for high-risk infants/children 8-19 months entering their second RSV season.
    • Recommendation for maternal RSV vaccination (Abrysvo) during 32-36 weeks gestation.
    • Recommendation for RSV vaccination in adults ≥60 years old using shared clinical decision-making.
  • These guidelines represent a paradigm shift in RSV prevention, moving from targeted prophylaxis to broader, population-level protection for infants and older adults.
• Evidence:
  • Nirsevimab: Landmark trials (MELODY, HARMONIE) demonstrated significant reductions in medically attended RSV LRTI and hospitalizations in healthy infants.
  • Maternal Vaccine (Abrysvo): The MATISSE trial showed high efficacy in preventing severe RSV LRTI in infants born to vaccinated mothers.
  • Adult Vaccines (Arexvy, Abrysvo): The AReSVi-006 (Arexvy) and RSVPRo (Abrysvo) trials demonstrated robust efficacy against RSV-associated LRTI in older adults.
• Controversies:
  • Implementation Challenges: Ensuring equitable access and uptake of nirsevimab (due to cost, supply chain, and newness) and vaccines across different settings.
  • Co-administration: Data on co-administration of RSV vaccines with other adult vaccines (e.g., flu, COVID-19) are emerging but require ongoing study.
  • Long-term Asthma Risk: While prevention of acute RSV is achieved, the impact of these new interventions on the long-term risk of asthma/wheezing remains an area of ongoing research.
  • Cost-effectiveness: Ongoing analyses are evaluating the long-term cost-effectiveness of these new interventions.

Key References

• Guidelines:
  • Centers for Disease Control and Prevention (CDC) - Advisory Committee on Immunization Practices (ACIP) Recommendations for RSV Immunization (published annually and updated as needed). Available at: https://www.cdc.gov/mmwr/ (search for RSV).
  • American Academy of Pediatrics (AAP) Clinical Practice Guideline: Management of Bronchiolitis. Pediatrics 2014;134(5):e1474-e1502. (Note: New guidelines for management are anticipated, but for prevention, ACIP is primary).
• Studies:
  • Nirsevimab: Hammitt LL, et al. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med 2022;386(9):837-846. (MELODY trial).
  • Maternal RSV Vaccine (Abrysvo): Kampmann B, et al. Bivalent RSV Prefusion F Protein Vaccine in Pregnancy. N Engl J Med 2023;388(16):1451-1464. (MATISSE trial).
  • RSV Vaccine for Adults (Arexvy): Papi A, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med 2023;388(7):595-608. (AReSVi-006 trial).
  • RSV Vaccine for Adults (Abrysvo): Walsh EE, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Protein Vaccine in Older Adults. N Engl J Med 2023;388(16):1465-1477. (RSVPRo trial).
• Reviews: Recent reviews on RSV prevention strategies incorporating the new vaccines and monoclonal antibodies published in major medical journals (e.g., Lancet, JAMA, New England Journal of Medicine).